OKYO Pharma
www.okyopharma.comOKYO Pharma focuses on: A novel class of membrane-anchored Chemerin receptor GPCR agonist that targets the inflammatory pathways to treat dry eye syndrome, uveitis and allergic conjunctivitis. An agonist for MAS-Related G Protein-Coupled Receptor (MRGPR), a non-opioid analgesic, for ocular and chronic pain management using novel topical and nasal formulations.
Read more
OKYO Pharma focuses on: A novel class of membrane-anchored Chemerin receptor GPCR agonist that targets the inflammatory pathways to treat dry eye syndrome, uveitis and allergic conjunctivitis. An agonist for MAS-Related G Protein-Coupled Receptor (MRGPR), a non-opioid analgesic, for ocular and chronic pain management using novel topical and nasal formulations.
Read more
Country
City (Headquarters)
London
Industry
Employees
1-10
Founded
2018
Social
Employees statistics
View all employeesPotential Decision Makers
Chief Scientific Officer
Email ****** @****.comPhone (***) ****-****Chief Executive Officer
Email ****** @****.comPhone (***) ****-****Independent Non - Executive Director
Email ****** @****.comPhone (***) ****-****
Technologies
(15)
Reach decision makers at OKYO Pharma
Free credits every month!
OKYO Pharma FAQ
London, United Kingdom
Pharmaceutical Manufacturing
